How Dihexa Works: The HGF/c-Met Pathway Explained

Mechanism Overview

Dihexa operates through a single, well-defined molecular target: the hepatocyte growth factor (HGF) receptor, also known as c-Met (cellular mesenchymal-to-epithelial transition factor). When Dihexa enters the brain and encounters neurons expressing c-Met, it binds to this receptor and activates a cascade of intracellular signalling events that result in profound changes to neural structure and function.

This mechanism is fundamentally different from conventional nootropics and pharmaceuticals, which typically work by modulating neurotransmitter systems — blocking reuptake of dopamine, enhancing GABA signalling, or blocking glutamate receptors. Dihexa, by contrast, activates a growth and repair pathway that triggers lasting structural changes to neural circuitry.

The HGF/c-Met pathway is one of the most ancient and evolutionarily conserved signalling systems in biology. It is active during brain development, controlling neuronal migration, differentiation, and synapse formation. In adult brains, this pathway is largely quiescent but retains the capacity to be reactivated. Dihexa's innovation is in reawakening this dormant system to promote neural plasticity, regeneration, and cognitive enhancement even in aged brains.

Hepatocyte Growth Factor (HGF) in the Brain

Hepatocyte growth factor was first discovered and characterised in liver tissue, where it regulates hepatocyte proliferation and tissue regeneration. However, HGF is now known to be produced throughout the body, including in the brain, where it plays critical roles in neural development and repair. In the central nervous system, HGF is synthesised primarily by glial cells — particularly microglia and astrocytes — and functions as a neuroprotective and neuroregenerative factor.

HGF signalling in the brain is involved in multiple processes:

• Neuronal survival and neuroprotection: HGF suppresses apoptosis (programmed cell death) and protects neurons from excitotoxicity and oxidative stress.
• Neurite outgrowth: HGF promotes the extension of axons and dendrites, allowing neurons to form new connections.
• Synaptic plasticity: HGF enhances the ability of synapses to strengthen or weaken in response to activity.
• Anti-inflammatory effects: HGF regulates microglial activation and cytokine production, reducing neuroinflammation.
• Blood-brain barrier integrity: HGF maintains the tight junctions that form the blood-brain barrier.

Under normal, healthy conditions, baseline levels of endogenous HGF provide tonic neuroprotective signalling. However, in aging, disease states, or after injury, HGF levels may be insufficient to maintain optimal neural function or to promote repair. Dihexa, as an HGF pathway agonist, theoretically augments this system by providing additional receptor activation beyond what endogenous HGF alone achieves.

The advantage of targeting HGF signalling rather than introducing exogenous HGF protein is that Dihexa is a small synthetic peptide that can cross the blood-brain barrier, resist enzymatic degradation, and be given orally. Native HGF protein, by contrast, is a large growth factor that cannot enter the brain from the systemic circulation and must be administered intracerebrally.

The c-Met Receptor and Signal Transduction

c-Met is a receptor tyrosine kinase — a cell surface protein that receives signals from growth factors and transmits them into the cell's nucleus. When HGF (or, in the case of Dihexa, an HGF-like peptide) binds to c-Met, the receptor undergoes a conformational change that brings two receptor molecules together in a process called dimerisation. This proximity allows each c-Met to phosphorylate (add phosphate groups) to the other, activating their intracellular kinase domains.

Once activated, c-Met initiates several interconnected signalling cascades:

• PI3K/Akt pathway: Promotes neuronal survival and growth by inhibiting apoptosis and activating anabolic processes.
• MAPK/ERK pathway: Drives gene expression changes that support neural plasticity and synapse formation.
• PLC-γ pathway: Regulates calcium signalling, which is essential for synaptic plasticity and the induction of long-term potentiation.
• Wnt/β-catenin pathway: Promotes dendritic spine formation and stabilisation.

These pathways are not isolated; they cross-talk and amplify each other, creating a robust and coordinated response to c-Met activation. The activation of multiple pathways simultaneously is thought to be one reason why the HGF/c-Met system is so effective at promoting comprehensive neural remodelling.

Importantly, c-Met signalling is not a "one-and-done" event. Activation of c-Met at the neuronal cell surface initiates gene transcription in the nucleus, leading to the expression of proteins that support neural growth and plasticity. These include growth factors like BDNF, synaptic proteins like PSD-95, and cytoskeletal proteins that remodel dendritic spines. The complete cascade from c-Met activation to observable structural changes takes hours to days.

Synaptogenesis: Building New Neuronal Connections

Synaptogenesis is the formation of new synaptic connections between neurons — the creation of new communication links in the neural network. In the developing brain, synaptogenesis is rapid and prolific, allowing the brain to wire itself according to genetic instructions and early experience. In the mature adult brain, synaptogenesis continues but at a much slower rate; it is thought to be the cellular basis of learning and memory formation.

Dihexa has been demonstrated to enhance synaptogenesis in cultured neurons and in rodent brains. When neurons are exposed to Dihexa, the number of synapses increases, and the synapses are often of higher quality — stronger, more stable, and more responsive to stimulation. This effect is mediated through c-Met activation and the downstream signalling pathways described above.

The mechanism by which HGF/c-Met signalling promotes synaptogenesis involves several steps:

1. c-Met activation in the postsynaptic neuron (the receiving cell) triggers calcium influx and activates kinases.
2. These signals cause the postsynaptic cell to increase synthesis of receptors, scaffolding proteins, and neurotrophic factors.
3. The postsynaptic cell secretes factors (including BDNF) that act on the presynaptic terminal (the sending cell) and promote neurotransmitter release machinery assembly.
4. New synapses are formed or existing weak synapses are stabilised and strengthened.

From a cognitive perspective, enhanced synaptogenesis is thought to increase the capacity of the brain to form memories, learn new information, and adapt to new environments. More synapses mean more potential circuit configurations and more bandwidth for information processing. This is why synaptogenesis is considered a fundamental mechanism of cognitive enhancement.

It is important to note that increased synaptogenesis does not automatically lead to cognitive improvement. The structure and organisation of neural circuits matter as much as the sheer number of synapses. However, in the context of learning and memory tasks, enhanced synaptogenesis in the appropriate brain regions (such as the hippocampus) is generally associated with improved performance in preclinical models.

Dendritic Spine Formation and Enlargement

Dendritic spines are small, mushroom-shaped protrusions on the dendrites of neurons that form the postsynaptic side of synapses. They are the primary sites where neurons receive input from other neurons, and their size, number, and shape directly correlate with learning ability, memory capacity, and cognitive performance. Spines are dynamic structures that grow and shrink in response to experience and activity — a phenomenon called structural plasticity.

Preclinical studies of Dihexa have demonstrated a robust effect on dendritic spine density and morphology. In a landmark study by McCoy et al. (2013), exposure to Dihexa led to approximately a 3-fold increase in dendritic spine density in cultured hippocampal neurons and in the hippocampi of rodents. This increase was sustained over the observation period and was associated with enhanced performance on memory tasks.

The mechanism by which Dihexa increases dendritic spine density involves several molecular steps:

• c-Met activation in postsynaptic neurons initiates signalling cascades that promote cytoskeletal remodelling.
• Key cytoskeletal proteins, particularly actin and its regulatory proteins, are recruited to dendritic sites.
• These proteins cause the membrane to protrude outward, forming new spine-like structures.
• Simultaneously, synaptic proteins and neurotransmitter receptors are recruited to these new spines, converting them into functional synapses.
• The activation of Wnt/β-catenin signalling by HGF/c-Met pathway promotes the stabilisation and maturation of these spines.

Beyond the increase in spine number, Dihexa also enhances spine size. Larger spines generally have stronger synaptic transmission and are more stable, suggesting that Dihexa-induced spines are of high quality. The ability to increase both spine density and spine size distinguishes Dihexa from some other interventions that increase spine number but may produce immature or weak spines.

From a behavioral standpoint, animals treated with Dihexa often show improvements in spatial memory, object recognition, and other hippocampus-dependent cognitive tasks. These improvements correlate closely with the increase in dendritic spine density, suggesting that the structural changes are causally related to the cognitive benefits.

Long-Term Potentiation (LTP) Enhancement

Long-term potentiation is a persistent increase in synaptic strength that occurs when two neurons fire together repeatedly — often expressed as "neurons that fire together, wire together." LTP is considered one of the most important mechanisms of learning and memory at the synaptic level. When you learn something new, the synapses involved in encoding that memory undergo LTP, becoming stronger and more efficient at transmitting signals.

LTP is typically induced by strong activation of glutamate receptors (particularly NMDA receptors) on the postsynaptic neuron. This activation allows calcium to flood into the postsynaptic cell, triggering a cascade of signalling events that strengthen the synapse. This cascade includes activation of kinases, insertion of additional AMPA receptors into the membrane, and enlargement of the postsynaptic density (the protein-rich region opposite the presynaptic terminal).

Dihexa has been shown to enhance LTP through its effects on the HGF/c-Met pathway. The mechanism appears to involve several steps:

1. c-Met activation increases the phosphorylation and activation of kinases involved in LTP induction (particularly CaMKII, calcium-calmodulin-dependent protein kinase II).
2. HGF/c-Met signalling enhances NMDA receptor function, lowering the threshold for LTP induction.
3. The pathway promotes the trafficking of AMPA receptors to the cell membrane, increasing the postsynaptic response to glutamate.
4. c-Met activation also modulates the phosphorylation state of key synaptic proteins, facilitating their recruitment to the postsynaptic density.

The net effect is that synapses from Dihexa-treated neurons show enhanced capacity for LTP: they undergo larger and more persistent increases in strength when stimulated appropriately. This enhanced plasticity is thought to underlie improved learning and memory in behavioral tests.

It is important to note that enhanced LTP capacity does not automatically lead to better learning. The brain must also be able to "decide" which synapses to strengthen and which to weaken (long-term depression, LTD) based on the relevance and importance of the learned information. However, in the context of relevant learning tasks, enhanced LTP capacity generally translates to better learning and memory retention.

AMPA Receptor Activity and Miniature Excitatory Postsynaptic Currents

AMPA receptors are a type of glutamate receptor found on the postsynaptic membrane that mediate fast synaptic transmission. They are the primary receptors responsible for the immediate electrical response of the postsynaptic neuron to glutamate released from the presynaptic terminal. The strength of synaptic transmission is partially determined by the number of AMPA receptors in the postsynaptic membrane — more receptors mean stronger responses to the same amount of glutamate.

Miniature excitatory postsynaptic currents (mEPSCs) are small electrical currents that occur spontaneously due to the random release of single vesicles of glutamate from the presynaptic terminal. The frequency and amplitude of mEPSCs provide a sensitive readout of synaptic strength: frequency reflects the presynaptic release rate, while amplitude reflects the postsynaptic response (largely determined by AMPA receptor number and function).

Dihexa increases both the frequency and amplitude of mEPSCs in neurons, indicating both increased presynaptic release and increased postsynaptic responsiveness. This is consistent with the compound's broader effects on synaptogenesis and synaptic strength. The increase in mEPSC amplitude specifically reflects increased AMPA receptor insertion and enhanced postsynaptic receptor function, while the increase in frequency suggests enhanced presynaptic vesicle release probability.

The mechanisms by which Dihexa enhances AMPA receptor activity include:

• Increased AMPA receptor gene expression through c-Met-dependent transcription factors.
• Enhanced trafficking of AMPA receptors from intracellular stores to the cell membrane in response to activity.
• Phosphorylation and activation of AMPA receptors, increasing their single-channel conductance.
• Enhanced surface stabilisation of AMPA receptors, increasing their dwell time in the membrane.

From a functional perspective, enhanced AMPA receptor activity translates to more efficient synaptic transmission and a higher signal-to-noise ratio in neural circuits. This contributes to improved information processing and cognitive function.

Gene Expression Changes and Lasting Effects

One of the most remarkable aspects of HGF/c-Met signalling is that it initiates cascades of gene expression that produce lasting changes to neural structure and function. Unlike drugs that produce acute, reversible effects dependent on their continued presence, Dihexa's effects are thought to persist long after the compound has been metabolised and cleared from the body because they are encoded in altered gene expression and new protein synthesis.

Activation of c-Met triggers transcription factors that bind to regulatory DNA sequences in the nucleus and increase the transcription of genes involved in:

• Synaptic proteins: PSD-95, synapsins, AMPA and NMDA receptors, and other scaffolding and structural proteins of synapses.
• Cytoskeletal proteins: Actin and actin-binding proteins that form the structural foundation of dendritic spines.
• Growth factors: BDNF, NGF, and other neurotrophic factors that support neuronal survival and plasticity.
• Calcium signalling proteins: Calmodulin, CaMKII, and other proteins that mediate activity-dependent changes in synapses.
• Anti-apoptotic proteins: Bcl-2 family members and other survival factors that protect neurons from death.

These gene expression changes begin within hours of c-Met activation and continue for days or weeks. The newly synthesised proteins become incorporated into dendritic spines, synaptic structures, and intracellular signalling machinery. Over time, this leads to a remodelling of neural circuits that is visible at the structural level (more spines, stronger synapses) and measurable at the functional level (better learning and memory).

The persistence of Dihexa's effects is thought to result from this durable gene expression response. Even after Dihexa is metabolised and removed from the body, the neurons retain the structural and functional changes induced by the compound. This is conceptually similar to how learning produces lasting changes in the brain — the learning experience triggers gene expression that encodes memory, and those memories persist even after the learning experience is over.

However, it should be noted that the durability of Dihexa's effects in humans is unknown. Preclinical studies suggest lasting effects, but human studies are needed to determine whether the structural changes observed in rodents translate to long-lasting cognitive improvements in people.

Neural Consolidation During Sleep

Sleep is critical for memory consolidation — the process by which newly learned information is transferred from short-term, fragile memory to stable long-term memory. During sleep, the brain replays neural patterns that were active during learning, and synapses undergo targeted strengthening and weakening (synaptic homeostasis) that integrate the new memories into existing networks.

One mechanism by which Dihexa may enhance learning and memory is by potentiating the neural consolidation that occurs during sleep. Although direct evidence of this mechanism in Dihexa-treated subjects is limited, the compound's effects on synaptic plasticity machinery (enhanced LTP, increased AMPA receptors, upregulated plasticity genes) should theoretically enhance the capacity of sleep to consolidate memories.

The proposed mechanism would be:

1. During waking learning, synapses involved in encoding the learned information are strengthened (LTP) and new synapses are formed, aided by Dihexa's effects on dendritic spine formation and synaptic protein expression.
2. During subsequent sleep, these synapses are replayed and undergo further consolidation and refinement through slow-wave sleep oscillations.
3. Dihexa's enhancement of the molecular machinery supporting synaptic plasticity allows sleep-dependent consolidation to be more effective, leading to more robust and lasting memory formation.

This hypothesis is speculative and requires direct experimental testing, but it provides a plausible mechanism by which Dihexa's acute effects on plasticity could lead to lasting cognitive benefits through interaction with natural sleep-dependent consolidation processes.

Dihexa vs BDNF: A Nuanced Comparison

Brain-derived neurotrophic factor (BDNF) is perhaps the most well-known neurotrophic factor and has been the focus of intense research for decades. BDNF binds to the TrkB receptor on neurons and promotes neuronal survival, growth, and synaptic plasticity. In many ways, BDNF and Dihexa have similar end goals — they both promote neural growth and plasticity — but they achieve these goals through different receptors and signalling pathways.

In some preclinical assays, particularly those measuring dendritic spine formation in cultured neurons, Dihexa appears to be substantially more potent than BDNF on a molar basis. That is, lower concentrations of Dihexa achieve the same level of spine formation as higher concentrations of BDNF. This has led to the "10 million times more potent" claim, which is technically accurate for that specific assay but requires significant contextualisation.

Why the difference in potency? Dihexa and BDNF work through different receptors:

• BDNF activates the TrkB receptor, a receptor tyrosine kinase with a different structure and signalling profile than c-Met.
• Dihexa activates the HGF/c-Met receptor, which may engage more directly or efficiently with pathways that drive dendritic spine formation in the assay conditions used.
• The assay may be biased toward measuring c-Met-dependent synaptogenesis, making Dihexa appear more potent than it would in assays that measure other plasticity mechanisms.

Are they functionally equivalent? No. BDNF and Dihexa target different receptors and promote partially distinct downstream effects. BDNF has been extensively studied and has roles in many aspects of neural function beyond spine formation. Dihexa, being a more recent discovery, has a narrower evidence base. The relative importance of their respective pathways in human brain function is not yet clear.

Could they work synergistically? Possibly. Since BDNF and Dihexa activate different receptors and downstream pathways, there is no inherent reason they should be redundant. In fact, they might complement each other and produce additive or synergistic effects. However, no preclinical studies have directly examined combined administration of Dihexa and BDNF.

Clinical implications of the potency difference: Higher molar potency does not automatically translate to clinical advantages. It is possible to engineer a compound to be extremely potent in a dish but ineffective in living organisms. Conversely, a less potent compound might perform better clinically due to superior pharmacokinetics, safety profile, or engagement of complementary pathways. Without head-to-head human clinical trials, it is impossible to determine whether Dihexa's in vitro potency advantage translates to clinical superiority over BDNF or BDNF-enhancing interventions.

Timeline of Effects: From Minutes to Weeks

The effects of Dihexa unfold over multiple timescales, from the rapid molecular events that occur within minutes of drug exposure to the structural changes that take days or weeks to manifest:

• Minutes: Dihexa binds to c-Met receptors and activates receptor tyrosine kinase activity. Intracellular signalling cascades (PI3K/Akt, MAPK/ERK, PLC-γ) are initiated.
• Minutes to hours: Calcium signalling changes occur, affecting synaptic transmission and LTP induction. Kinase cascades phosphorylate substrate proteins, altering their activity.
• Hours: Gene transcription is initiated. mRNA encoding synaptic proteins, growth factors, and cytoskeletal proteins begins to accumulate.
• Hours to days: New proteins are synthesised and incorporated into dendritic spines and synaptic structures. AMPA receptors are trafficked to the cell membrane. Dendritic spine density and size begin to increase.
• Days to weeks: Structural remodelling becomes prominent. Dendritic spines fully mature, synaptic connections stabilise, and the circuit-level effects of synaptogenesis become apparent in behavioral measures of learning and memory.

This multi-timescale action is characteristic of compounds that work through growth factor pathways. The acute molecular effects set in motion cascades that produce lasting structural changes. This is both an advantage (longer-lasting effects) and a potential limitation (slower onset, delayed benefits).

Learn More About Dihexa

For an introduction to what Dihexa is, including its chemical structure and origins, see What Is Dihexa? Complete Guide to PNB-0408.

For information on the potential benefits of enhanced neural plasticity and synaptogenesis, read Potential Benefits of Dihexa: Cognitive Enhancement and Neuroprotection.

For a review of the research evidence supporting these mechanisms, visit Research and Studies.

For information on fosgonimeton (a related compound targeting the same pathway), see Fosgonimeton: HGF/c-Met Activator.

For more detailed explanations of technical terms, consult our Comprehensive Glossary.